Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Barclays analyst Gena Wang has initiated coverage on Intellia Therapeutics (NASDAQ: NTLA) with an Underweight rating. The firm has set a price target of $8 for the company's stock.